Circulating Sclerostin Levels Are Decreased in Patients with Endogenous Hypercortisolism and Increase after Treatment | Zendy

Antoon H van Lierop | Zendy; Anke W. van der Eerden | Zendy; Neveen A. T. Hamdy | Zendy; A. R. M. M. Hermus | Zendy; Martin den Heijer | Zendy; Socrates E. Papapoulos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Sclerostin Levels Are Decreased in Patients with Endogenous Hypercortisolism and Increase after Treatment

Author(s) -

Antoon H van Lierop,

Anke W. van der Eerden,

Neveen A. T. Hamdy,

A. R. M. M. Hermus,

Martin den Heijer,

Socrates E. Papapoulos

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2218

Subject(s) - sclerostin , n terminal telopeptide , endocrinology , medicine , endogeny , procollagen peptidase , bone remodeling , adrenalectomy , chemistry , alkaline phosphatase , osteocalcin , wnt signaling pathway , biochemistry , gene , enzyme

Increased bone fragility is a frequent complication of hypercortisolism due predominantly to suppression of bone formation. Sclerostin is an osteocyte-produced negative regulator of bone formation, which is up-regulated by glucocorticoids in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research